RECRUITING

A Registry for People With Lung Cancer

Conditions

Lung Cancer Lung Cancer Stage I lung cancer stage 1 segmentectomy Memorial Sloan Kettering Cancer Center 24-127

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.

Official Title

Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108

Quick Facts

Study Start:2024-05-15

Study Completion:2029-05-15

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06424327

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Age ≥18 years * Clinical stage I tumor (AJCC 8th edition) suitable for segmentectomy, according to the treating thoracic surgeon * Pathology of NSCLC * Patients must undergo segmentectomy for a peripheral lesion ≤2 cm to be included in the primary analysis. Individual ligation of the segmental artery(s) and segmental bronchus is the minimum definition for a segmentectomy. Division of the segmental vein and intraoperative frozen section to assess surgical margins and N1 lymph nodes are strongly encouraged, but the absence of either is not a criterion for exclusion. * Patients with ground-glass opacities will have their tumor size recorded on the basis of the size of the solid component. * Any non-lung cancer treated in the past with no obvious recurrence or ongoing treatment is not a criterion for exclusion. * The registry study will be monitored by Thoracic Surgery team at MSK. * This study will be in collaboration with the Thoracic Surgical Oncology Group (TSOG) of the American Association for Thoracic Surgery.	* Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years * History of chemotherapy or radiation therapy for a previous lung cancer * Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery * Carcinoid tumors * History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix * Actively receiving treatment for other malignancies * Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis. * Multi-segmental resection from the same lobe is not a criterion for exclusion.

Inclusion Criteria

Exclusion Criteria

* Age ≥18 years
* Clinical stage I tumor (AJCC 8th edition) suitable for segmentectomy, according to the treating thoracic surgeon
* Pathology of NSCLC
* Patients must undergo segmentectomy for a peripheral lesion ≤2 cm to be included in the primary analysis. Individual ligation of the segmental artery(s) and segmental bronchus is the minimum definition for a segmentectomy. Division of the segmental vein and intraoperative frozen section to assess surgical margins and N1 lymph nodes are strongly encouraged, but the absence of either is not a criterion for exclusion.
* Patients with ground-glass opacities will have their tumor size recorded on the basis of the size of the solid component.
* Any non-lung cancer treated in the past with no obvious recurrence or ongoing treatment is not a criterion for exclusion.
* The registry study will be monitored by Thoracic Surgery team at MSK.
* This study will be in collaboration with the Thoracic Surgical Oncology Group (TSOG) of the American Association for Thoracic Surgery.

* Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years
* History of chemotherapy or radiation therapy for a previous lung cancer
* Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery
* Carcinoid tumors
* History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix
* Actively receiving treatment for other malignancies
* Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis.
* Multi-segmental resection from the same lobe is not a criterion for exclusion.

Contacts and Locations

Study Contact

David Jones, MD

CONTACT

212-639-6428

jonesd2@mskcc.org

Bernard Park, MD

CONTACT

646-888-3346

parkb@mskcc.org

Principal Investigator

David Jones, MD

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920

United States

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748

United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645

United States

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

Commack, New York, 11725

United States

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604

United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065

United States

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553

United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

David Jones, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-15

Study Completion Date2029-05-15

Study Record Updates

Study Start Date2024-05-15

Study Completion Date2029-05-15

Terms related to this study

Keywords Provided by Researchers

lung cancer
lung cancer stage 1
segmentectomy
Memorial Sloan Kettering Cancer Center
24-127

Additional Relevant MeSH Terms

Lung Cancer
Lung Cancer Stage I